RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
Open Access
- 21 February 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 17 (1), 24
- https://doi.org/10.1186/s13058-015-0538-7
Abstract
RANKL is important in mammary gland development during pregnancy and mediates the initiation and progression of progesterone-induced breast cancer. No clinical data are available on the effect of pregnancy on RANK/RANKL expression in young breast cancer patients. We used our previously published dataset of 65 pregnant and 130 matched young breast cancer patients with full clinical, pathological, and survival information. 85% of patients had available transcriptomic data as well. RANK/RANKL expression by immunohistochemistry using H-score on the primary tumor and adjacent normal tissue was performed. We examined the difference in expression of RANK/RANKL between pregnant and non-pregnant patients and their association with clinicopathological features and prognosis. We also evaluated genes and pathways associated with RANK/RANKL expression on primary tumors. RANKL but not RANK expression was more prevalent in the pregnant group, both on the tumor and adjacent normal tissue, independent of other clinicopathological factors (both P <0.001). 18.7% of pregnant and 5.3% of non-pregnant patients had tumors showing ≥10% of cells with 3+ RANKL expression. RANKL expression was significantly higher in progesterone receptor-positive, and luminal A-like tumors, with negative correlation with Ki-67 (all P <0.001). On the contrary, RANK expression was higher in triple negative tumors (P <0.001). Using false discovery rate <0.05, 151 and 1,207 genes were significantly correlated with tumor-expressed RANKL and RANK expression by immunohistochemistry, respectively. High RANKL expression within primary tumor was associated with pathways related to mammary gland development, bone resorption, T-cell proliferation and regulation of chemotaxis, while RANK expression was associated with immune response and proliferation pathways. At a median follow-up of 65 months, neither RANK nor RANKL expression within tumor was associated with disease free survival in pregnant or non-pregnant group. Pregnancy increases RANKL expression both in normal breast and primary tumors. These results could guide further development of RANKL-targeted therapy.Keywords
This publication has 23 references indexed in Scilit:
- Biology of breast cancer in young womenBreast Cancer Research, 2014
- RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phaseBreast Cancer Research and Treatment, 2014
- Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression ProfilingClinical Cancer Research, 2012
- Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and MetastasisClinical Cancer Research, 2012
- Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signallingNature, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesisNature, 2010
- Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancerNature, 2010
- Control of mammary stem cell function by steroid hormone signallingNature, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009